Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.81 |
| ▸ | NPC1 | O15118 | 7/20 | 0.81 |
| ▸ | MEN1 | O00255 | 7/20 | 0.81 |
| ▸ | MAPT | P10636 | 5/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.81 |
| ▸ | POLB | P06746 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.81 |
| ▸ | RELA | Q04206 | 1/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | SCD | O00767 | 7/20 | 0.67 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Frentizole SCHEMBL599582 | 0.90 | RAB9A (1.00) | RAB9AKMT2ANPC1MEN1MAPT | |
| Frentizole SCHEMBL11433152 | 0.88 | RAB9A (0.98) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL4918017 | 0.87 | RAB9A (0.79) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL4924519 | 0.87 | RAB9A (0.79) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL212825 | 0.87 | KMT2A (0.76) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL16554145 | 0.87 | SCD (0.88) | RAB9AKMT2ANPC1MEN1SMN1; SMN2 | |
| SCHEMBL209812 | 0.86 | NPC1 (0.70) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL2759504 | 0.85 | RAB9A (0.76) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL213883 | 0.85 | GSK3B (0.78) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL4909124 | 0.84 | RAB9A (0.74) | RAB9AKMT2ANPC1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | RAB9A 3036/4885KMT2A 68/4885NPC1 1293/4885 |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | UBQLN1, NEDD4, UCHL5 | RAB9A 3771/4885KMT2A 1591/4885NPC1 3462/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | RAB9A 3239/4885KMT2A 123/4885NPC1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.